Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:22.860Z.
Calculation as of: 2026-10-06T13:25:22.860Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3eea2ebb4dfb8ae449a8fc068c41cc3e6d53bf63d9a404ece64f578f5b067b33
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$547.86M
EV/EBIT Ratio
N/A
TTM Avg
189.50x
3Y Avg
189.50x
5Y Avg
189.50x
Market Cap
$487.30M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $519.25M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | N/A | 64.08x | 60.43x | 132.37x |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | N/A | 189.50x | 189.50x | 189.50x |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 5.92x | 17.76x | 17.76x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
